Logo Image
|Videos|October 7, 2020

Using the New Indication for Esketamine to Treat Patients with Major Depressive Disorder

Dr Sanacora discusses the new indication for esketamine, SPRAVATO®, and how it might be used to treat patients with Major Depressive Disorder with acute risk of suicide ideation.

Dr Sanacora is a Professor of Psychiatry at Yale University, Director of the Yale Depression Research Program, and Co-Director of the Yale New Haven Hospital Interventional Psychiatry Service.

Related Content

Latest CME

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care
Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

View more
Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia
Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

View more
Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder
Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

View more